Breaking News Instant updates and real-time market news.

MENT

Mentor Graphics

$27.52

-0.4 (-1.43%)

, QSII

Quality Systems

$11.48

0.28 (2.50%)

20:43
10/16/16
10/16
20:43
10/16/16
20:43

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Mentor Graphics (MENT), a maker of electronics design software, is working with an investment bank to explore strategic options, according Reuters. Elsewhere in M&A news, Quality Systems (QSII) jumped in late trading Friday following media reports pointing to a possible sale. 2. Constellation Brands (STZ) is nearing a deal to sell its Canadian wine unit in a transaction valued at roughly C$1B, according to the Wall Street Journal. 3. Adding to a number of recent departures at the restaurant giant, McDonald's (MCD) could see another set of high-level exits this week, including the retirement of chief field officer Karen King, the Wall Street Journal said. 4. Tesla (TSLA) CEO Elon Musk delayed the company's upcoming product announcement to Wednesday from Monday. 5. U.S. Steel (X), PVH Corp (PVH), FMC (FMC) and Samsung (SSNLF) were discussed positively by Barron's, while the significant short interest in Amazon (AMZN) was also highlighted by the publication.

MENT

Mentor Graphics

$27.52

-0.4 (-1.43%)

QSII

Quality Systems

$11.48

0.28 (2.50%)

STZ

Constellation Brands

$169.46

0.52 (0.31%)

MCD

McDonald's

$114.09

-1.32 (-1.14%)

TSLA

Tesla

$196.51

-3.73 (-1.86%)

X

U.S. Steel

$16.42

-0.03 (-0.18%)

PVH

PVH Corp.

$110.34

-0.97 (-0.87%)

FMC

FMC Corporation

$46.56

0.2 (0.43%)

SSNLF

Samsung

AMZN

Amazon.com

$822.96

-6.32 (-0.76%)

  • 21

    Oct

  • 23

    Oct

  • 27

    Oct

  • 27

    Oct

  • 27

    Oct

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 09

    Nov

  • 14

    Nov

  • 29

    Nov

MENT Mentor Graphics
$27.52

-0.4 (-1.43%)

10/10/16
DADA
10/10/16
UPGRADE
DADA
Buy
Mentor Graphics upgraded on multiple catalysts at DA Davidson
As noted earlier, DA Davidson upgraded Mentor Graphics to Buy from Neutral. Analyst Thomas Diffely says that the company is benefiting from multiple catalysts, including exposure to vertical markets that will enable multi-year growth, solid cash flow, and an activist investor that can help the company unlock value. He thinks that the company can benefit by optimizing its operations, and he finds the stock's valuation attractive. Target to $32 from $24.
10/10/16
DADA
10/10/16
UPGRADE
DADA
Buy
Mentor Graphics upgraded to Buy from Neutral at DA Davidson
08/19/16
DADA
08/19/16
DOWNGRADE
DADA
Neutral
Mentor Graphics downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Thomas Diffely downgraded Mentor Graphics to Neutral following solid Q2 results based on share valuation.
02/22/16
02/22/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on the today's top five analyst upgrades with this list compiled by The Fly: 1. CSX (CSX) upgraded to Buy from Neutral at BofA/Merrill by analyst Ken Hoexter, who also increased his price target to $28 from $25. He said overall industry volume comps begin to get easier beginning in April and believes CSX's multiple should expand as volume stabilize and coal pressures subside. Hoexter also upgraded Knight Transportation (KNX) and Swift Transport (SWFT) to Buy from Neutral and Werner (WERN) and Genesee & Wyoming (GWR) upgraded to Neutral from Underperform. 2. WellCare (WCG) upgraded to Overweight from Neutral at JPMorgan by analyst Gary Taylor, who raised his price target to $114 from $80. Taylor cited an improved Medicare Advantage outlook following the Centers for Medicare and Medicaid Services' 2017 Advance Notice and said the agency's decision to not explicitly recoup the 2017 HIP Holiday is "quite material" to WellCare. WEllCare was also upgraded to Neutral from Underperform at Bofa/Merrill. 3. Cree (CREE) upgraded to Overweight from Neutral at Piper Jaffray by analyst Mike Ritzenthaler after his firm's channel checks with lighting distributors indicated solid volume growth in the order books for 2016. 4. Mentor Graphics (MENT) upgraded to Buy from Neutral at DA Davidson as it believes that the company's announcement that it will repurchase 8.1M shares from Carl Icahn, along with what the firm sees as stabilizing industry fundamentals, has improved the stock's risk/reward ratio. 5. IMAX (IMAX) upgraded to Outperform from Netural at Wedbush by analyst Michael Pachter. The valuation is favorable while the company is seeing an improving pace of screen installations and an improving premium film slate in 2016, Pachter said. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
QSII Quality Systems
$11.48

0.28 (2.50%)

10/14/16
10/14/16
NO CHANGE

Quality Systems hired UBS to explore a sale, Dealreporter says citing sources
Quality Systems has hired UBS to explore a potential sale, Dealreporter says citing sources. Last week, Quality Systems management conducted presentations for several strategic buyers and financial sponsors, the sources said.
04/14/16
LEER
04/14/16
NO CHANGE
Target $150
LEER
Market Perform
Leerink cautious on athenahealth as replacement market slows down
Leerink analyst David Larsen is "incrementally" more cautious on athenahealth (ATHN) following a survey of 40 physician practices. While the analyst believes the company has an "excellent" model and management team, he expects the replacement market to slow down, and the longer-term doc-add and bookings growth comps to become more challenging. Larsen added that the data is also positive for Cerner (CERN) and Epic, negative for Quality Systems (QSII), and slightly positive for Allscripts (MDRX). The analyst reiterates a Market Perform and $150 price target on athenahealth's shares.
06/08/16
LEER
06/08/16
NO CHANGE
Target $16
LEER
Market Perform
Pieces in place for Quality Systems turn-around, says Leerink
Leerink analyst David Larsen says he is now incrementally more positive on Quality Systems's stock after attending the company's analyst day. Recurring revenue continues to rise and management is focused on growing earnings, the analyst tells investors in a research note. However, Larsen believes Quality Systems still faces "significant attrition" of its core base, and is worried that Q1 bookings may disappoint. The analyst reiterates a Market Perform rating and $16 price target on the shares as he waits to see more turn-around traction before getting more positive.
10/05/16
UBSW
10/05/16
INITIATION
Target $10.5
UBSW
Sell
Quality Systems initiated with a Sell at UBS
Target $10.50.
STZ Constellation Brands
$169.46

0.52 (0.31%)

09/15/16
FBCO
09/15/16
INITIATION
FBCO
Neutral
Constellation Brands initiated with a Neutral at Credit Suisse
09/15/16
FBCO
09/15/16
INITIATION
Target $178
FBCO
Neutral
Constellation Brands initiated with a Neutral at Credit Suisse
Credit Suisse analyst Laurent Grandet initiated coverage on Constellation Brands with a Neutral and a $178 price target saying high expectations are built into shares.
09/16/16
09/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoPro (GPRO) initiated with a Buy at BofA/Merrill. 2. JetBlue (JBLU) initiated with an Outperform at Imperial Capital. 3. PepsiCo (PEP), Dr Pepper Snapple (DPS), and Monster Beverage (MNST) were initiated with an Outperform at Credit Suisse, while the firm initiated Boston Beer (SAM) with an Underperform. Credit Suisse also initiated Coca-Cola (KO) and Constellation Brands (STZ) with a Neutral. 4. lululemon (LULU) initiated with a Positive at Susquehanna. 5. Target (TGT) coverage assumed with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
RBCM
09/28/16
NO CHANGE
RBCM
Constellation Brands removed from Focus List at RBC Capital
RBC Capital analyst Nik Modi, noting that Constellation Brands' stock is up 16% this year, thinks that the stock could pause in the near-term "around the company's results." He notes that analysts are already expecting the company to report beat and raise results. Modi keeps a $181 price target and Outperform rating on the shares, but he removed the stock from the firm's Focus List.
MCD McDonald's
$114.09

-1.32 (-1.14%)

10/10/16
TLSY
10/10/16
INITIATION
Target $130
TLSY
Outperform
McDonald's initiated with an Outperform at Telsey Advisory
Telsey Advisory analyst Robert Derrington initiated McDonald's with an Outperform and a $130 price target.
09/14/16
JPMS
09/14/16
NO CHANGE
JPMS
JPMorgan says buy three restaurant stocks after recent weakness
JPMorgan analyst John Ivankoe recommends using recent volatility to buy McDonald's (MCD), Starbucks (SBUX) and Yum! Brands (YUM), but not Chipotle Mexican Grill (CMG). On Chipotle, the analyst recommends using meaningful price weakness, closer to or below $400, to accumulate the shares.
09/07/16
BUCK
09/07/16
NO CHANGE
BUCK
Chipotle probably won't be bought by McDonald's, says Buckingham
Buckingham analyst John Zolidis says he's been asked "more than once" if Chipotle could be acquired by McDonald's. The analyst says that Chipotle would provide McDonald's with "a growth vehicle," as McDonald's could accelerate Chipotle's international expansion and use its expertise to convert the burrito chain to a franchised model. However, the analyst says there is little chance of such a deal occurring. Additionally, after an investor announced a 10% stake in Chipotle last night, the analyst does not think there's a clear path to unlocking shareholder value in Chipotle. However, he continues to expect Chipotle's sales to rebound to levels that are similar to those it had before its food safety issues. He reiterates a $547 price target and Buy rating.
09/15/16
FBCO
09/15/16
NO CHANGE
Target $132
FBCO
Outperform
McDonald's SSS checks sluggish but stable, says Credit Suisse
Credit Suisse analyst Jason West said US franchise same-store-sales checks remained sluggish in July and August and are likely running in the +1-2% range, inline with investor expectations. West expects same-store-sales to be flat to slightly down in Q4 due to difficult comps but believes investors are already pricing in a weak Q4 for the US business. The analyst continues to view McDonald's defensive characteristics as attractive in the current environment and its discounted valuation relative to peers as unwarranted. West reiterates his Outperform rating and $132 price target on McDonald's shares.
TSLA Tesla
$196.51

-3.73 (-1.86%)

10/13/16
OPCO
10/13/16
NO CHANGE
OPCO
Perform
Likelihood of Tesla, SolarCity deal closing has increased, says Oppenheimer
With Tesla (TSLA) setting the shareholder vote on November 17 for the SolarCity (SCTY) acquisition and detailing board activity at both companies in its latest filing, Oppenheimer analyst Colin Rusch believes the likelihood of the deal closing has increased. The analyst expects investors to begin to refocus on the evolution of product offerings along with capital plans and margin performance, and sees a significantly scaled-back SolarCity given staff cuts and voluntary departures. Oppenheimer has a Perform rating on Tesla's shares.
10/06/16
10/06/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Buy at Goldman with analyst David Tamberrino saying he sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. 2. JPMorgan (JPM) downgraded to Hold from Buy at Sandler O'Neill with analyst Jeffery Harte citing relative share outperformance. 3. Abercrombie & Fitch (ANF) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jessica Schmidt saying the elevated promotions add to other headwinds, including the fact that the teen space is "overstored" and faces soft consumer demand and weak tourism. 4. American Express (AXP) downgraded to Reduce from Neutral at Nomura with analyst Bill Carcache saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. 5. Lowe's (LOW) downgraded to Neutral from Buy at Cleveland Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
GSCO
10/06/16
NO CHANGE
GSCO
Autos and Autos Parts sector downgraded to Cautious from Neutral at Goldman
Goldman analyst David Tamberrino downgraded the Autos and Auto Parts sector to Cautious from Neutral saying the US Auto cycle peaked in 2015 and is being held up by increasing OEM incentives. The analyst said OEM earnings will decline in 2017/2018 as negative pricing and lower production pressure North American results, but expects suppliers' earnings to hold up longer. The analyst sees upside to Delphi (DLPH) and Harman (HAR) given exposure to secular growth areas and upside to Goodyear Tire (GT) given secular HVA tire growth. Tamberrino downgraded Lear (LEA) to Sell citing elevated expectations and valuation, cut BorgWarner (BWA) to Neutral on valuation, downgraded Tesla (TSLA) to Neutral on execution risk and capital deployment, and upgraded AutoNation (AN) to Neutral given a more defensive business.
10/06/16
GSCO
10/06/16
DOWNGRADE
GSCO
Neutral
Tesla downgraded to Neutral from Buy at Goldman
Goldman analyst David Tamberrino downgraded Tesla to Neutral and lowered his price target to $185 from $240. Tamberrino sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. The analyst said there is room for downward estimate revisions as volume ramps slower and spending grows. Tamberrino's 2016 earnigns estimate of (59c) is above the Street's (93c), but estimates for 2017 through 2019 are on average 48% below consensus.
X U.S. Steel
$16.42

-0.03 (-0.18%)

10/13/16
MACQ
10/13/16
NO CHANGE
Target $13
MACQ
Underperform
U.S. Steel price target lowered to $13 from $20 at Macquarie
Macquarie analyst Aldo Mazzaferro said steel pricing in recent weeks has fallen to slightly less than $500 a ton in spot markets, but said the good news is there is less incentive for imports to lower US pricing. The analyst cut U.S. Steel's earnings expectations on the price weakness and continued disappointing steel volumes and now estimates EBITDA at $487M this year and $765M in 2018 and lowered his price target to $13 from $20. Mazzaferro rates U.S. Steel an Underperform.
09/23/16
FBCO
09/23/16
NO CHANGE
Target $29
FBCO
Outperform
Credit Suisse says U.S. Steel shares are 'very' undervalued
Credit Suisse analyst Curt Woodworth believes U.S. Steel shares are "very" undervalued and views the sharp pullback on the widely anticipated hot rolled sheet price correction as overdone. Woodworth sees significant upside potential into 2017 as conversion costs continue to fall, U.S. Steel realizes ASP increases in annual contracts, OCTG moves higher as excess inventory is worked down, and Europe benefits from higher prices in both spot and contract tons. The analyst rates U.S. Steel an Outperform with a $29 price target on shares.
09/26/16
JPMS
09/26/16
NO CHANGE
Target $37
JPMS
Overweight
U.S. Steel recent weakness brings buying opportunity, says JPMorgan
JPMorgan analyst Michael Gambardella believes the recent weakness in shares of U.S. Steel provides a buying opportunity. The majority of the supply cuts that caused steel prices and stocks to rally earlier this year remain in place, Gambardella tells investors in a research note. He reiterates an Overweight rating on U.S. Steel with a $37 price target.
09/19/16
09/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. 2. Wells Fargo (WFC) upgraded to Outperform from Neutral at Baird analyst David George saying he believes the recent pullback is a buying opportunity. 3. Lockheed Martin (LMT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Sam Pearlstein saying he believes the company's earnings can grow 20% per year through 2020. 4. U.S. Steel (X), AK Steel (AKS), and Olympic Steel (ZEUS) were upgraded to Sector Weight from Underweight at KeyBanc with analyst Ivan Marcuse saying the stocks at current levels better reflect the more competitive market conditions he expects in Q4 and 2017. 5. Mattel (MAT) upgraded to Buy from Neutral at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PVH PVH Corp.
$110.34

-0.97 (-0.87%)

09/30/16
GUGG
09/30/16
INITIATION
Target $125
GUGG
Buy
PVH Corp. initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated PVH Corp with a Buy and a $125 price target.
09/12/16
WELS
09/12/16
INITIATION
WELS
Outperform
PVH Corp. resumed with an Outperform at Wells Fargo
Wells Fargo analyst Ike Boruchow resumed coverage of PVH Corp. with an Outperform rating and $125-$127 price target range.
10/07/16
PIPR
10/07/16
NO CHANGE
Target $124
PIPR
Overweight
Piper remains buyer of PVH after management meetings
After traveling with management, Piper Jaffray analyst Erinn Murphy says she remains a buyer of PVH Corp. shares. International trends are accelerating and PVH is a "beat & raise" story, Murphy tells investors in a research note. The analyst sees $11 per share in earnings power over the next four years. She reiterates an Overweight rating on the shares with a $124 price target.
09/12/16
WELS
09/12/16
INITIATION
WELS
Outperform
PVH Corp. coverage resumed at Wells Fargo
As noted earlier, Wells Fargo resumed coverage of PVH with an Outperform rating. The firm says that the company has multiple catalysts that should enable it to report "relatively impressive" results going forward. Specifically, the firm is upbeat on the company's Calvin Klein brand and its new Chief Creative Officer. Target $125-$127.
FMC FMC Corporation
$46.56

0.2 (0.43%)

04/21/16
04/21/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Las Vegas Sands (LVS) downgraded to Neutral at JPMorgan by analyst Joseph Greff, who said the shares are likely to be range-bound until the Macau market shows signs of stabilization. He adds that the stock at current levels has "gotten ahead of itself" and expectations for improving Macau fundamentals. 2. Cummins (CMI) downgraded to Underperform from Neutral at Baird with analyst David Leiker citing stretched valuation and expects performance to remain under pressure from the challenging NAFTA Class 8 environment. 3. Knight Transportation (KNX) downgraded to Outperform at Raymond James based on less than 15% upside to the revised price target. It was also downgraded at Stifel due to the lower than expected Q1 EPS and the belief that the company did not show normal seasonal strength at the end of March. 4. Werner (WERN) downgraded to Hold at Stifel citing the company's Q1 EPS miss, soft pricing and a tough freight environment. 5. FMC Corporation (FMC) downgraded to Neutral at Credit Suisse by analyst Christopher Parkinson, who believes channel inventories in the Americas are bloated and will take time to draw down and that the pricing environment will remain challenging through Q2 and Q3. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/19/16
JEFF
05/19/16
NO CHANGE
Target $95
JEFF
Hold
Jefferies views Bayer buyout of Monsanto as 'relatively unlikely'
After Monsanto (MON) confirmed an unsolicited offer from Bayer (BAYRY), Jefferies analyst Laurence Alexander says he still believes a transaction is "relatively unlikely." The analyst expects Monsanto to object to Bayer's offer given its conviction in its research and development pipeline and longer-term competitive advantages. Shares of Syngenta (SYT) and DuPont (DD) could be pressured as regulatory scrutiny is likely to intensify should Monsanto get acquired, and BASF (BASFY) could sell off on investor concerns of a potential counter-bid, Alexander tells investors in a research note. On the other hand, he sees a potential Monsanto takeover as positive for shares of Novozymes (NVZMY) and FMC Corporation (FMC). "A further roll-up of 'specialty generic' agrichemical assets could entice capital, and FMC would be a plausible anchor for such an attempt," the analyst writes. He has a Hold rating on Monsanto with a $95 price target.
04/14/16
LYON
04/14/16
INITIATION
Target $43
LYON
Outperform
FMC Corporation initiated with an Outperform at CLSA
Target $43.
04/21/16
FBCO
04/21/16
DOWNGRADE
Target $43
FBCO
Neutral
FMC Corporation downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analysts led by Christopher Parkinson downgraded FMC Corporation to Neutral and lowered its price target to $43 from $45. The believes channel inventories in the Americas are bloated and will take time to draw down and that the pricing environment will remain challenging through Q2 and Q3. Parkinson believes the recent rally in FMC shares reflect "euphoric" intermediate term expectations and are fully valued.
SSNLF Samsung

10/12/16
WELS
10/12/16
NO CHANGE
WELS
Market Perform
Wells doesn't see Apple as biggest beneficiary from Samsung issues
Wells Fargo analyst Maynard Um attributes the recent rally in shares of Apple (AAPL), at least in part, to Samsung's (SSNLF) issues with its Note 7 phones. Apple gained an incremental $14B in market capitalization at its intraday peak, which the analyst believes embeds more than 3M of incremental iPhone 7 Plus units. Samsung's production halt will help Apple, but other Android vendors with 5.7 inch phones could see a bigger benefit if Android users prefer to stick with Android, Um tells investors in a research note. He points out that LG, Kyocera, and Microsoft (MFST) have 5.7 inch Android phones at U.S. carriers. Um thinks expectations for Apple into earnings "have risen materially." He keeps a Market Perform rating on the iPhone maker. Apple closed yesterday up 25c to $116.30.
10/11/16
DRXL
10/11/16
NO CHANGE
Target $185
DRXL
Buy
Apple could gain 8M iPhone units from Note 7 troubles, says Drexel Hamilton
Drexel Hamilton analyst Brian White estimates Apple (AAPL) has an opportunity to pick up "at least" 8 million incremental iPhone units in calendar year 2016 due to the Galaxy Note 7 being scrapped, noting that original market expectations were for Samsung (SSNLF) to ship about 10M-14M Galaxy Note 7 units in the second half of this year. The "fiasco" could permanently damage Samsung's smartphone brand, resulting in Apple market share gains, White added. The analyst keeps a Buy rating and $185 price target on Apple shares.
08/01/16
NEED
08/01/16
NO CHANGE
Target $65
NEED
Buy
Synaptics price target lowered to $65 from $88 at Needham
Needham analyst Rajvindra Gill lowered his price target for Synaptics (SYNA) to $65 from $88 on a lower earnings multiple as he remains uncertain on whether the company has secured the OLED DDIC for Apple's (AAPL) iPhone 8 versus an internal Samsung (SSNLF) solution. The analyst reiterates a Buy rating on Synaptics' shares, saying the company will remain one of the leaders in the display markets.
10/12/16
RHCO
10/12/16
NO CHANGE
RHCO
Best Buy, GameStop should be able to sidestep Note 7 impact, says SunTrust
SunTrust analyst David Magee, in two separate notes to investors, said that he believes Samsung's (SSNLF) troubles with the Galaxy Note 7 should not translate to shortfalls for either GameStop's (GME) mobile stores or for Best Buy (BBY), as in both cases most of their customers will simply pick different models. Sony's VR headset and other upcoming products in the category are "ideal for customers to try out in stores," added Magee, who keeps a Buy rating on both GameStop and Best Buy.
AMZN Amazon.com
$822.96

-6.32 (-0.76%)

10/14/16
RBCM
10/14/16
NO CHANGE
RBCM
VMware partnership with Amazon positive, says RBC Capital
After VMware (VMW) and Amazon Web Services (AMZN) announced a strategic alliance, RBC Capital analyst Matthew Hedberg says that the deal could enable enterprises to more easily combine Amazon Web Services with VMware software. Hedberg says that the deal gives VMware another sales channel and enables it to be considered more of a player in the hybrid cloud arena. The analyst keeps an Outperform rating on VMware.
10/13/16
JPMS
10/13/16
NO CHANGE
JPMS
Overweight
JPMorgan says buy GoPro on today's weakness
JPMorgan analyst Paul Coster views today's weakness in shares of GoPro (GPRO) as a buying opportunity. While GoPro is not shipping Hero 5 via the Amazon (AMZN) channel today, Amazon has been consistently a top five channel partner for the action camera maker, Coster tells investors in a research note. He expects Amazon shipments to resume by month end and points out the hiatus does not apply to international Amazon sales. The one month impact would be 30,000 Hero 5 units through this channel, or less than $10M in GoPro sales, Coster estimates. He calls the decision to halt shipments to Amazon voluntary and believes the company has alternative distribution channels for the new product. Coster has an Overweight rating on GoPro. The shares are down 22c to $14.08 after Piper Jaffray this morning highlighted that Hero shipments to Amazon have stopped.
10/13/16
PIPR
10/13/16
NO CHANGE
Target $9
PIPR
Underweight
GoPro currently not shipping to Amazon, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says she uncovered that GoPro (GPRO) is not currently selling to Amazon (AMZN), at least domestically, in a change that occurred over the last three weeks. In a follow-up research note after speaking to management, Murphy clarified that the pause in shipping to Amazon is planned to be temporary. GoPro plans to resume shipping to Amazon at the end of October, Murphy adds. The action camera maker has been shipping to Best Buy (BBY), other partners and its own GoPro.com channel in the meantime, she points out. Nonetheless, the analyst believes the disruption at Amazon was not contemplated in guidance. Murphy is "incrementally concerned" on GoPro's ability to reach its second half of 2016 guidance. The analyst reiterates an Underweight rating on the shares with a $9 price target. The stock closed yesterday down 72c to $14.30.
10/12/16
MSCO
10/12/16
NO CHANGE
Target $110
MSCO
Morgan Stanley sees 'un-grandfathering' peaking for Netflix in Q3
Morgan Stanley analyst Benjamin Swinburne believes the market expects Netflix (NFLX) to report Q3 domestic net subscriber additions that fall short of the company's 300K forecast. However, he thinks the impact of "un-grandfathering" will peak in Q3 and that the percentage of U.S. members seeing price increases will begin to fade in Q4. While acknowledging that Amazon (AMZN) continues to grow as a competitor for content and time spent, Swinburne notes that local and regional players in many markets continue to struggle. The analyst keeps an Overweight rating and $110 price target on Netflix shares.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.